scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage
Search Results
Oncology Research Program
Oncology Research Program
scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) Plus Weekly Cetuximab Plus Radiation Therapy
New Issues in Systemic Therapy for Ovarian Cancer
Deborah K. Armstrong
Most patients with ovarian cancer are diagnosed with advanced-stage cancer. Debulking surgery followed by chemotherapy is recommended. The standard front-line regimen is 6 cycles of paclitaxel plus carboplatin, with docetaxel a reasonable
Point: Combination Versus Single-Agent Chemotherapy: The Argument for Sequential Single Agents
Alison K. Conlin and Andrew D. Seidman
anthracycline-containing chemotherapy. 304 Study Group . J Clin Oncol 1999 ; 17 : 1413 – 1424 . 6. Bishop JF Dewar J Toner GC . Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated
CLO21-024: Serial Circulating Tumor DNA Analysis for Treatment Monitoring in an Inflammatory Triple-Negative Breast Cancer Patient
Urmeel Patel, Nicole Hook, Meenakshi Malhotra, Perry Olshan, Paul R. Billings, Alexey Aleshin, and Angel Rodriguez
patient underwent neoadjuvant chemotherapy with dose dense AC (ddAC) followed by paclitaxel. Following one month, the patient underwent radical mastectomy, followed by adjuvant treatment and periodic radiological imaging, along with circulating tumor DNA
Oncology Research Program
-agent tivozanib in patients with platinum-resistant ovarian cancer Contact: Nikki Neubauer, MD • 312-472-4684 Rachel Bers, BS • 312-472-5726 • r-bers@northwestern.edu ClinicalTrials.gov Identifier: NCT01853644 Phase I Trial of Intraperitoneal Nab-Paclitaxel
Oncology Research Program
-639-5449 ClinicalTrials.gov Identifier: NCT01111825 Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity Principal Investigator: Mihaela Cristea, MD Condition
Oncology Research Program
, Vanderbilt-Ingram Cancer Center • 800-811-8480 ClinicalTrials.gov Identifier: NCT00983268 A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer Principal Investigator
Therapy of Adenocarcinoma of Unknown Primary: Are We Making Progress?
F. Anthony Greco
Med 2004 ; 350 : 2335 – 2342 . 4. Sandler AB Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer . N Engl J Med 2006 ; 355 : 2542 – 2550 . 5. Moore MJ Goldstein D Hamm J . Erlotinib
Management of Recurrent or Metastatic Cervical Cancer
Presented by: Nadeem R. Abu-Rustum
with external-beam RT, as well as interstitial brachytherapy, which is a sophisticated technology for the treatment of central pelvic recurrences. Use of modern chemotherapy regimens containing a combination of platinum and paclitaxel with drugs such
